What are the different types of diabetes along with type 1 and type 2? How to diagnose every type clinically, by history, examination, and on the basis of investigations? What are the treatment options for each type? Individualized treatment, surveillance , prognosis based on the severity of the disease, other co-morbidities, and other risk factors
Reading File
Finding Sources
Finding Sources
Searching PubMed
"diabetes mellitus" AND "classification diagnosis treatment"
Finding Sources
Searching PubMed
"diabetes mellitus" AND "guidelines"
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Goldman-Cecil Medicine and Harrison's to build a thorough answer. Let me compile the full response.
Diabetes Mellitus: Complete Clinical Guide
CLASSIFICATION OF DIABETES MELLITUS
The American Diabetes Association (ADA) recognizes four main clinical categories of diabetes mellitus (DM), plus prediabetes:
| Category | Core Mechanism |
|---|---|
| Type 1 DM (T1DM) | Autoimmune beta-cell destruction → absolute insulin deficiency |
| Type 2 DM (T2DM) | Progressive beta-cell secretory failure + insulin resistance |
| Gestational DM (GDM) | Glucose intolerance diagnosed during pregnancy (not preexisting) |
| Other Specific Types | Monogenic (MODY), exocrine pancreatic disease, endocrinopathies, drugs |
| Prediabetes | Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) - intermediate state |
(Creasy & Resnik's Maternal-Fetal Medicine; Goldman-Cecil Medicine)
DIAGNOSTIC CRITERIA (All Adults, Non-Pregnant)
Any one of the following criteria confirms DM (must be confirmed on a repeat test in asymptomatic individuals):
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| FPG (Fasting Plasma Glucose) | <5.6 mmol/L (<100 mg/dL) | 5.6–6.9 mmol/L (100–125 mg/dL) | ≥7.0 mmol/L (≥126 mg/dL) |
| 2-h PG (75-g OGTT) | <7.8 mmol/L (<140 mg/dL) | 7.8–11.0 mmol/L (140–199 mg/dL) | ≥11.1 mmol/L (≥200 mg/dL) |
| HbA1c | <5.6% (<38 mmol/mol) | 5.7–6.4% (39–47 mmol/mol) | ≥6.5% (≥48 mmol/mol) |
| Random PG + symptoms | - | - | ≥11.1 mmol/L (≥200 mg/dL) |
(Harrison's Principles of Internal Medicine 22nd ed., 2025; Goldman-Cecil Medicine)
TYPE 1 DIABETES MELLITUS (T1DM)
Pathophysiology
Cellular-mediated autoimmune destruction of pancreatic beta cells in genetically susceptible individuals, triggered by an undefined environmental agent (enteroviruses likely). Results in absolute insulin deficiency. Accounts for 5-10% of all DM.
Clinical Presentation (History)
- Onset typically in children/adolescents, but can occur in adults (LADA variant)
- Classic triad: Polyuria, polydipsia, polyphagia
- Weight loss - despite normal or increased appetite
- Fatigue, blurred vision
- Initial presentation may be diabetic ketoacidosis (DKA) - especially in children <5 years or those with limited healthcare access (13-80% worldwide present with DKA)
- Family history: risk 5-6% in siblings, 30% in monozygotic twins
- Associated autoimmune conditions: thyroid disease, Addison disease, vitiligo, celiac disease, autoimmune hepatitis, myasthenia gravis, pernicious anemia
Examination
- Thin/normal BMI
- Dehydration, Kussmaul breathing, fruity breath (DKA)
- Acanthosis nigricans absent (unlike T2DM)
- May show features of associated autoimmune conditions
Investigations
- Fasting/Random plasma glucose (as above)
- HbA1c ≥6.5%
- Autoantibodies (positive in 85-90%):
- Islet cell antibodies (ICA)
- Anti-insulin antibodies (IAA)
- Anti-GAD65 (glutamic acid decarboxylase)
- Anti-IA-2 and anti-IA-2beta (tyrosine phosphatases)
- Anti-ZnT8 (zinc transporter)
- C-peptide: Low/undetectable (confirms absolute deficiency)
- Urinalysis: Glycosuria, ketonuria in DKA
- ABG: Metabolic acidosis in DKA (pH <7.3)
- HLA typing: Research/confirmation (HLA-DR3/DR4 association)
Treatment
Insulin is mandatory and lifesaving. All T1DM patients require insulin - never oral agents alone.
Insulin regimens:
| Type | Examples | Onset | Peak | Duration |
|---|---|---|---|---|
| Rapid-acting analogues | Lispro, Aspart, Glulisine | 15-30 min | 30-90 min | 3-4 hr |
| Short-acting (Regular) | Human insulin | ~30 min | 2-4 hr | 5-8 hr |
| Intermediate (NPH) | Human NPH | 2-4 hr | 6-10 hr | 16-20 hr |
| Long-acting | Glargine U100, Detemir | 1.5-2 hr | Peakless | 16-20 hr |
| Ultra-long | Degludec U100/U200 | 1.5-2 hr | Peakless | >24 hr |
| Glargine U300 | - | 1.5-2 hr | Peakless | >24 hr |
Standard basal-bolus regimen: Total daily dose 0.3-1.0 unit/kg/day; ~50% basal, ~50% divided as prandial doses. Rule of thumb: 1 unit per 10-15g carbohydrate + correction factor.
Advanced delivery:
- Continuous subcutaneous insulin infusion (CSII/insulin pump)
- Automated insulin delivery (AID/"closed loop") - considered standard of care where available
- Continuous glucose monitoring (CGM) - monitors time-in-range (TIR), hypoglycemia detection
Non-insulin adjuncts for T1DM:
- Pramlintide (amylin analogue) - reduces postprandial glucose
- Off-label: SGLT2 inhibitors (with caution - DKA risk), metformin (weight/insulin dose reduction)
- Teplizumab (anti-CD3 antibody) - approved to delay Stage 3 T1DM in Stage 2 patients
(Goldman-Cecil Medicine; Harrison's 22nd ed., 2025)
TYPE 2 DIABETES MELLITUS (T2DM)
Pathophysiology
Progressive loss of beta-cell secretory function on the background of insulin resistance (primarily in muscle, fat, and liver). Caused by interaction of genetic factors (>100 loci, strongest: TCF7L2), metabolic stress, and inflammation.
Risk Factors
- BMI ≥30 (overweight ≥25, ≥23 in Asians)
- Age >35 years (screening from this age)
- First-degree relative with T2DM (3x risk; 40% if one parent; 70% if both parents)
- Monozygotic twin concordance 70%, dizygotic 20-30%
- Prior gestational diabetes or baby >4 kg
- PCOS, acanthosis nigricans
- Hypertension, HDL <35 mg/dL, TG >250 mg/dL
- Physical inactivity, sedentary lifestyle
- Ethnicity: Asian, African American, Hispanic, Native American, Pacific Islander
- Antipsychotic therapy, chronic glucocorticoid use
- Sleep apnea / chronic sleep deprivation
- Non-alcoholic fatty liver disease
Clinical Presentation (History)
- Insidious onset, often asymptomatic - diagnosed on screening
- Classical symptoms (polyuria, polydipsia, blurred vision) when significantly hyperglycemic
- Fatigue, recurrent infections (UTIs, skin infections, candidiasis)
- Erectile dysfunction, neuropathic symptoms (burning/tingling feet) in advanced disease
- Up to 10 years may pass before clinical diagnosis; complications may already be present
Examination
- Typically overweight/obese
- Acanthosis nigricans (neck, axillae - insulin resistance marker)
- Hypertension (co-morbidity)
- Features of complications: peripheral neuropathy, reduced foot pulses, retinopathy (fundoscopy), renal signs
Investigations
- FPG, HbA1c, 2-hr OGTT (same ADA criteria as above)
- C-peptide: Normal or elevated (distinguishes from T1DM)
- Autoantibodies: Negative (unless LADA - see below)
- Lipid profile (dyslipidemia common)
- Urine albumin-creatinine ratio (UACR) - microalbuminuria = early nephropathy
- eGFR (renal function)
- Liver enzymes (NAFLD association)
- ECG, echo (cardiovascular risk)
Screening
- All adults ≥35 years: every 3 years
- Earlier if overweight + any risk factor
- Screening tools: FPG or HbA1c (OGTT reserved for high-risk, cystic fibrosis, post-transplant)
Treatment
Step 1 - Lifestyle modification (always the foundation):
- Medical nutrition therapy: reduce refined carbohydrates and saturated fat; Mediterranean or DASH diet
- Exercise: ≥150 min/week moderate-intensity aerobic + resistance training
- Weight loss: 5-10% body weight significantly improves glycemic control
- Smoking cessation (doubles microvascular risk)
- Alcohol: women ≤1 drink/day, men ≤2 drinks/day
Step 2 - Pharmacologic therapy (individualized):
Most guidelines recommend metformin as first-line for most patients (unless contraindicated):
| Drug Class | Examples | HbA1c Reduction | Key Indication / Advantage | Cautions |
|---|---|---|---|---|
| Biguanides | Metformin | 1.0-1.5% | First-line; weight neutral/loss; CV benefit in obese | eGFR <30 (contraindicated); GI side effects |
| SGLT2 inhibitors | Empagliflozin, Dapagliflozin, Canagliflozin | 0.5-1.0% | Heart failure, CKD, CV disease - preferred add-on | UTI/genital infections, DKA risk (rare) |
| GLP-1 receptor agonists | Semaglutide, Liraglutide, Dulaglutide | 1.0-1.5% | Obesity, CVD, ASCVD - preferred; weight loss | GI side effects; injection (except oral semaglutide) |
| GLP-1/GIP dual agonist | Tirzepatide | 1.5-2.5% | Most weight loss of all agents; CV benefit | GI side effects |
| Sulfonylureas | Glipizide, Gliclazide, Glibenclamide | 1.0-1.5% | Low cost; high potency | Hypoglycemia, weight gain |
| DPP-4 inhibitors | Sitagliptin, Vildagliptin | 0.5-0.8% | Well tolerated, weight neutral | Higher cost; modest efficacy |
| Thiazolidinediones | Pioglitazone | 0.5-1.4% | Insulin resistance; NAFLD benefit | Fluid retention, heart failure, fractures |
| Alpha-glucosidase inhibitors | Acarbose | 0.5-0.8% | Postprandial glucose | GI flatulence; poor tolerability |
| Insulin | Basal ± prandial | Unlimited | When oral agents fail or HbA1c very high | Hypoglycemia, weight gain |
Individualized approach based on comorbidities:
- With established CVD or high CV risk: SGLT2 inhibitor OR GLP-1 agonist with proven CV benefit (empagliflozin, liraglutide, semaglutide, dulaglutide) are preferred after/with metformin
- With heart failure: SGLT2 inhibitors (dapagliflozin, empagliflozin) significantly reduce HF hospitalization
- With CKD: SGLT2 inhibitors slow CKD progression; adjust doses by eGFR; avoid metformin if eGFR <30
- With obesity: GLP-1 agonists or GLP-1/GIP agonists (tirzepatide, semaglutide) - significant weight loss
- Hypoglycemia risk (elderly, irregular meals): Avoid sulfonylureas; prefer DPP-4, SGLT2, GLP-1
- Cost constraints: Metformin + sulfonylurea remains a viable low-cost combination
(Goldman-Cecil Medicine, Harrison's 22nd ed., Katzung's Pharmacology 16th ed.)
GESTATIONAL DIABETES MELLITUS (GDM)
Pathophysiology
Physiologic insulin resistance from placental diabetogenic hormones (growth hormone, CRH, hPL, progesterone). Normal pregnancy = 60% reduction in insulin sensitivity. GDM occurs when beta-cell hyperplasia cannot compensate.
History / Risk Factors
- Prior GDM or macrosomic baby >4 kg
- Obesity, age >30 years, strong family history of T2DM
- Polycystic ovary syndrome
- Prior unexplained fetal loss
Examination
- Weight, BMI, blood pressure
- Fundal height (fetal size estimation - macrosomia)
- Fetal heart rate
Diagnosis
Screen all pregnant women at 24-28 weeks gestation:
Two-step approach (common in USA):
- 50-g GCT (non-fasting): If 1-hr glucose ≥130-140 mg/dL → proceed to Step 2
- 100-g 3-hr OGTT (fasting): Diagnosis if ≥2 of: FPG ≥95, 1-hr ≥180, 2-hr ≥155, 3-hr ≥140 mg/dL
One-step approach (IADPSG/WHO):
- 75-g 2-hr OGTT (fasting): Diagnosis if FPG ≥5.1, 1-hr ≥10.0, or 2-hr ≥8.5 mmol/L (any one value)
Glycemic targets in GDM:
- Fasting <95 mg/dL (5.3 mmol/L)
- 1-hr postprandial <140 mg/dL (7.8 mmol/L)
- 2-hr postprandial <120 mg/dL (6.7 mmol/L)
Treatment
- Lifestyle (dietary modification, physical activity, weight management) - sufficient in 70-85% of women
- Pharmacologic when targets not met:
- Insulin: most studied, preferred for safety
- Metformin: appears preferable as oral agent, but insulin often still needed
- Sulfonylureas: less preferred (fetal risks; glyburide crosses placenta)
- Most other anti-diabetic drugs: contraindicated in pregnancy
Postpartum
- Retest at 4-12 weeks postpartum with 75-g OGTT
- Lifelong screening every 1-3 years (35-60% develop T2DM within 10 years)
- Children: increased risk of obesity and T2DM
(Goldman-Cecil Medicine; Harrison's 22nd ed.)
OTHER SPECIFIC TYPES OF DIABETES
A. Monogenic Diabetes (MODY - Maturity-Onset Diabetes of the Young)
Definition: Autosomal dominant single-gene mutations impairing insulin secretion. Accounts for 1-3% of DM diagnosed under age 30 years.
| MODY Subtype | Gene Mutated | Key Feature | Treatment |
|---|---|---|---|
| MODY 1 | HNF-4α | Progressive hyperglycemia | Sulfonylureas |
| MODY 2 | Glucokinase | Mild, stable, nonprogressive hyperglycemia | Usually none needed (except in pregnancy) |
| MODY 3 | HNF-1α (most common, 30-65%) | Progressive decline; initially misdiagnosed as T1DM | Very sensitive to sulfonylureas |
| MODY 5 | HNF-1β | Renal cysts, pancreatic exocrine insufficiency, liver dysfunction | Insulin required; poor response to sulfonylureas |
| Others | PDX-1, NeuroD1, KLF11, etc. | Variable | Variable |
Clinical clues for MODY:
- Diabetes in ≥2 generations (autosomal dominant family history)
- Onset typically <25 years
- Non-obese
- Antibodies negative
- C-peptide positive
Diagnosis: Genetic panel testing (multigene sequencing)
B. Exocrine Pancreatic Diabetes (Type 3c / Pancreatogenic)
- Causes: Chronic pancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer, hemochromatosis
- Often associated with exocrine insufficiency (malabsorption, steatorrhea)
- Requires insulin; hypoglycemia risk is high due to co-existing glucagon deficiency
- Cystic fibrosis-related diabetes (CFRD): screen with annual OGTT from age 10 years (HbA1c unreliable due to hemolysis)
C. Endocrinopathy-Related Diabetes
- Acromegaly: GH excess → insulin resistance
- Cushing syndrome: Cortisol → hepatic gluconeogenesis + peripheral resistance
- Pheochromocytoma: Catecholamines → hepatic glucose output
- Glucagonoma: Glucagon excess → hyperglycemia
- Treatment: Address the primary endocrine disorder; often resolves or improves
D. Drug/Chemical-Induced Diabetes
- Glucocorticoids: Most common cause; predominantly postprandial hyperglycemia ("steroid diabetes")
- HIV/AIDS antiretrovirals (especially protease inhibitors)
- Post-organ transplantation (new-onset diabetes after transplantation, NODAT): immunosuppressants (tacrolimus, cyclosporine, steroids)
- Antipsychotics: Clozapine, olanzapine (weight gain + direct insulin resistance)
- Thiazide diuretics, beta-blockers: Mild glucose elevation
E. Other Genetic Syndromes
Associated diabetes: Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram syndrome (DIDMOAD), Prader-Willi syndrome, Friedreich ataxia, myotonic dystrophy.
F. Rare Immune-Mediated Forms
- Stiff-person syndrome: GAD antibodies
- Anti-insulin receptor antibodies (Type B insulin resistance)
- Immune checkpoint inhibitor-induced diabetes: Resembles T1DM; manage with insulin
LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA)
A special form often under-recognized - sometimes called "Type 1.5 DM":
- Adult onset (typically >30 years)
- Initially appears to behave like T2DM (not requiring insulin)
- Positive GAD65 antibodies (key distinguishing marker)
- C-peptide: low-normal initially, progressively declines
- Non-obese or mildly overweight
- Poor response to oral agents; progresses to insulin dependency
- Distinguish from T2DM using GAD antibody testing in: lean patients failing oral agents, those with another autoimmune condition
SURVEILLANCE AND MONITORING
Glycemic Monitoring
| Parameter | Target | Frequency |
|---|---|---|
| HbA1c | <7.0% (general); <6.5% (young, no CVD); <8.0% (elderly/frail/hypoglycemia prone) | Every 3 months if uncontrolled; every 6 months if stable |
| Fasting glucose | 80-130 mg/dL | Daily self-monitoring (SMBG) |
| Post-prandial glucose | <180 mg/dL | SMBG if on insulin |
| Time-in-range (CGM) | >70% of time 70-180 mg/dL | Continuous (CGM devices) |
Complication Screening
| Complication | Screening Test | Frequency |
|---|---|---|
| Nephropathy | UACR + eGFR | Annual |
| Retinopathy | Dilated fundoscopic exam | At diagnosis (T2DM), 5 yrs after diagnosis (T1DM); annually if present |
| Neuropathy | Monofilament foot exam, vibration, pinprick | Annual |
| Cardiovascular | Blood pressure, lipid profile, 10-yr ASCVD risk | Annual |
| NAFLD/NASH | LFTs, liver ultrasound | At diagnosis, periodic |
| Thyroid (T1DM) | TSH | At diagnosis, periodically |
| Celiac (T1DM) | Anti-tTG IgA | At diagnosis |
INDIVIDUALIZED TREATMENT TARGETS AND PROGNOSIS
Stratified by Severity and Comorbidities
Young, healthy patients (T1DM or T2DM, no CVD):
- Aggressive glycemic targets: HbA1c <6.5-7.0%
- Lifestyle optimization, prevention of complications
- For T1DM: CGM + AID system where available
- Prognosis: Near-normal life expectancy with excellent control
Older adults / Frail patients:
- Relaxed targets: HbA1c <7.5-8.5% (avoid hypoglycemia)
- Simplify regimen; avoid sulfonylureas (hypoglycemia risk)
- Deprescribe aggressive regimens; focus on quality of life
- Prognosis: Hypoglycemia and falls are major risks
With established cardiovascular disease / high CV risk:
- Add SGLT2 inhibitor OR GLP-1 agonist with proven CV outcome benefit
- Blood pressure target: <130/80 mmHg (ACEi/ARB preferred in DM)
- Statin therapy (high-intensity if ASCVD; moderate-intensity for primary prevention)
- Low-dose aspirin in secondary prevention only
With heart failure:
- SGLT2 inhibitors (reduce hospitalization, mortality)
- Avoid thiazolidinediones (fluid retention)
- Avoid saxagliptin/alogliptin (increased HF hospitalizations in trials)
With CKD:
- SGLT2 inhibitors: slow CKD progression (dapagliflozin, canagliflozin approved for this)
- GLP-1 agonists: additional renal protection
- ACEi/ARB for UACR >30 mg/g
- Adjust metformin: hold if eGFR <30; safe if eGFR 30-60 (reduce dose)
- Avoid sulfonylureas with active renal impairment (accumulation)
With obesity (BMI >30):
- GLP-1 agonist or GLP-1/GIP dual agonist (tirzepatide) - weight loss + glucose control
- Bariatric surgery: if BMI >35 (or >30 with uncontrolled T2DM) - can induce remission
- Lifestyle program targeting 5-15% weight loss
With NAFLD/NASH:
- Pioglitazone or GLP-1 agonists have liver benefit
- Avoid alcohol, hepatotoxic drugs
Pregnancy planning (preexisting DM):
- Achieve HbA1c <6.5% ideally before conception
- Switch to insulin (metformin may be acceptable)
- Stop ACEi/ARB, statins, most oral agents before conception
- Intensive fetal monitoring
Prognosis Overview
- T2DM reduces life expectancy at age 50 by ~6 years on average
- T1DM is associated with higher absolute cardiovascular risk but modern management has dramatically improved outcomes
- Early multifactorial intervention (glycemia + BP + lipids + lifestyle) is the strongest predictor of reduced complications and mortality
- GDM: prognosis excellent for the pregnancy with good control; lifetime risk of T2DM up to 50-60% - requires lifelong surveillance
COMPLICATION PREVENTION - SUMMARY
| Intervention | Benefit |
|---|---|
| HbA1c reduction | Reduces microvascular complications (retinopathy, nephropathy, neuropathy) |
| BP control (<130/80) | Reduces both micro- and macrovascular events |
| Statin therapy | Reduces MACE (myocardial infarction, stroke, death) |
| SGLT2 inhibitors | Reduces HF, CKD progression, CV death |
| GLP-1 agonists | Reduces MACE, weight, and renal events |
| ACEi/ARB | Renoprotective; reduces proteinuria progression |
| Smoking cessation | Reduces all-cause and cardiovascular mortality |
| Aspirin | Secondary prevention only |
| Foot care / education | Reduces amputation risk |
Sources:
- Goldman-Cecil Medicine International Edition, Chapter 210 (Type 1 & 2 DM, GDM management)
- Harrison's Principles of Internal Medicine 22nd ed. (2025), Chapter 415 (Classification, Diagnosis, Pathophysiology, Treatment)
- Creasy & Resnik's Maternal-Fetal Medicine (Classification of DM in pregnancy)
- Symptom to Diagnosis: An Evidence-Based Guide, 4th ed. (Differential diagnosis approach)
- Katzung's Basic and Clinical Pharmacology, 16th ed. (Drug classes for T2DM)
- Thompson & Thompson Genetics in Medicine, 9th ed. (MODY / monogenic diabetes)
- ADA Standards of Medical Care in Diabetes 2024 (ISPAD Guidelines PMID 39662065; PMID 39675348)
This is a shared conversation. Sign in to Orris to start your own chat.